{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:04:11Z","timestamp":1783609451365,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ymthe.2024.11.021","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T03:35:42Z","timestamp":1731987342000},"page":"4381-4393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Longitudinal imaging of therapeutic enzyme expression after gene therapy for Fabry disease using positron emission tomography and the radiotracer [18F]AGAL"],"prefix":"10.1016","volume":"33","author":[{"given":"Charalambos","family":"Kaittanis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Teceno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoann","family":"Petibon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin Hye","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony P.","family":"Belanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise M.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quang-De","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanida","family":"Ruangsiriluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya","family":"Mukherji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian C.","family":"Constantinescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy Llopis","family":"Amenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarav","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mugdha","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwana","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipeng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"McQuade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T.","family":"Winkelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2790-175X","authenticated-orcid":false,"given":"Talakad G.","family":"Lohith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.11.021_bib1","doi-asserted-by":"crossref","first-page":"f153","DOI":"10.1093\/europace\/eux261","article-title":"Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice","volume":"20","author":"Baig","year":"2018","journal-title":"Europace."},{"key":"10.1016\/j.ymthe.2024.11.021_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22010206","article-title":"Fabry Disease Therapy: State-of-the-Art and Current Challenges","volume":"22","author":"Azevedo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.11.021_bib3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/bj2000143","article-title":"Turnover of beta-galactosidase in fibroblasts from patients with genetically different types of beta-galactosidase deficiency","volume":"200","author":"Van Diggelen","year":"1981","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymthe.2024.11.021_bib4","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1002\/emmm.201202287","article-title":"Gene therapy on the move","volume":"5","author":"Kaufmann","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2024.11.021_bib5","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.omtm.2023.03.014","article-title":"Gene therapy for cross-correction of somatic organs and the CNS in mucopolysaccharidosis II in rodents and non-human primates","volume":"29","author":"Chen","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.11.021_bib6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11307-008-0149-0","article-title":"Basic evaluation of FES-hERL PET tracer-reporter gene system for in vivo monitoring of adenoviral-mediated gene therapy","volume":"10","author":"Lohith","year":"2008","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.ymthe.2024.11.021_bib7","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/sj.gt.3302278","article-title":"Molecular imaging of gene therapy for cancer","volume":"11","author":"Shah","year":"2004","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2024.11.021_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28207144","article-title":"Radiosynthesis and Early Evaluation of a Positron Emission Tomography Imaging Probe [18F]AGAL Targeting Alpha-Galactosidase A Enzyme for Fabry Disease","volume":"28","author":"Lohith","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ymthe.2024.11.021_bib9","doi-asserted-by":"crossref","first-page":"11622","DOI":"10.1021\/ja507040n","article-title":"Potent and selective activity-based probes for GH27 human retaining alpha-galactosidases","volume":"136","author":"Willems","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ymthe.2024.11.021_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/genes8090232","article-title":"Effects of Cellular Methylation on Transgene Expression and Site-Specific Integration of Adeno-Associated Virus","volume":"8","author":"Chanda","year":"2017","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ymthe.2024.11.021_bib11","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40265-019-01090-4","article-title":"Migalastat: A Review in Fabry Disease","volume":"79","author":"McCafferty","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2024.11.021_bib12","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/cpdd.941","article-title":"Migalastat Tissue Distribution: Extrapolation From Mice to Humans Using Pharmacokinetic Modeling and Comparison With Agalsidase Beta Tissue Distribution in Mice","volume":"10","author":"Wu","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ymthe.2024.11.021_bib13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.neuroimage.2013.10.068","article-title":"Retest imaging of [11C]NOP-1A binding to nociceptin\/orphanin FQ peptide (NOP) receptors in the brain of healthy humans","volume":"87","author":"Lohith","year":"2014","journal-title":"Neuroimage"},{"key":"10.1016\/j.ymthe.2024.11.021_bib14","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00259-013-2512-x","article-title":"Suggested pathway to assess radiation safety of [18F]-labeled PET tracers for first-in-human studies","volume":"40","author":"Zanotti-Fregonara","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ymthe.2024.11.021_bib15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging Issues in AAV-Mediated In Vivo Gene Therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.11.021_bib16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/cge.13546","article-title":"Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients","volume":"96","author":"Germain","year":"2019","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymthe.2024.11.021_bib17","article-title":"The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts","volume":"19","author":"Germain","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymthe.2024.11.021_bib18","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00216-005-3239-8","article-title":"Fast fingerprinting by MALDI-TOF mass spectrometry of urinary sediment glycosphingolipids in Fabry disease","volume":"382","author":"Touboul","year":"2005","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.ymthe.2024.11.021_bib19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/gim.2018.31","article-title":"Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis","volume":"21","author":"Maruyama","year":"2019","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2024.11.021_bib20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","article-title":"Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2024.11.021_bib21","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","article-title":"Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy","volume":"22","author":"Sakuraba","year":"2018","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.ymthe.2024.11.021_bib22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ymgme.2018.04.007","article-title":"The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - A systematic literature review by a European panel of experts","volume":"126","author":"Spada","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2024.11.021_bib23","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00467-012-2222-9","article-title":"Renal complications of Fabry disease in children","volume":"28","author":"Najafian","year":"2013","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.ymthe.2024.11.021_bib24","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1021\/acs.bioconjchem.6b00561","article-title":"Click Chemistry and Radiochemistry: The First 10 Years","volume":"27","author":"Meyer","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ymthe.2024.11.021_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag2196","article-title":"Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma","volume":"9","author":"Keu","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2024.11.021_bib26","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1038\/s41467-021-24524-8","article-title":"Gene therapy for aromatic L-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons","volume":"12","author":"Pearson","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.11.021_bib27","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.drudis.2019.12.010","article-title":"Reporter gene imaging and its role in imaging-based drug development","volume":"25","author":"Shaikh","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ymthe.2024.11.021_bib28","doi-asserted-by":"crossref","first-page":"374","DOI":"10.7150\/thno.3677","article-title":"Positron emission tomography reporter genes and reporter probes: gene and cell therapy applications","volume":"2","author":"Yaghoubi","year":"2012","journal-title":"Theranostics"},{"key":"10.1016\/j.ymthe.2024.11.021_bib29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ymthe.2019.10.007","article-title":"Imaging CAR T Cell Trafficking with eDHFR as a PET Reporter Gene","volume":"28","author":"Sellmyer","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.11.021_bib30","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ymthe.2021.11.005","article-title":"Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency","volume":"30","author":"Tai","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.11.021_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ph16020320","article-title":"Treatment of Fabry Disease: Established and Emerging Therapies","volume":"16","author":"Umer","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ymthe.2024.11.021_bib32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1102\/1470-7330.2013.0005","article-title":"PET\/MR: a paradigm shift","volume":"13","author":"Gaertner","year":"2013","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.ymthe.2024.11.021_bib33","article-title":"Advantages and Applications of Total-Body PET Scanning","volume":"12","author":"Katal","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ymthe.2024.11.021_bib34","doi-asserted-by":"crossref","first-page":"5690","DOI":"10.1039\/C5OB00532A","article-title":"Galacto configured N-aminoaziridines: a new type of irreversible inhibitor of beta-galactosidases","volume":"13","author":"Alcaide","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ymthe.2024.11.021_bib35","doi-asserted-by":"crossref","first-page":"10139","DOI":"10.1021\/jo051645q","article-title":"A short synthesis of (+)-cyclophellitol","volume":"70","author":"Hansen","year":"2005","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ymthe.2024.11.021_bib36","doi-asserted-by":"crossref","first-page":"12079","DOI":"10.1021\/ja202610x","article-title":"Galacto-configured aminocyclitol phytoceramides are potent in vivo invariant natural killer T cell stimulators","volume":"133","author":"Harrak","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ymthe.2024.11.021_bib37","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1089\/hum.2023.222","article-title":"Developing gene therapy for mitigating multisystemic pathology in Fabry disease: proof of concept in an aggravated mouse model","volume":"35","author":"Boukharov","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.11.021_bib38","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1021\/acschemneuro.0c00802","article-title":"In Vitro Evaluation of [3H]CPPC as a Tool Radioligand for CSF-1R","volume":"12","author":"Knight","year":"2021","journal-title":"ACS Chem. Neurosci."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624007482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624007482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:25:01Z","timestamp":1782505501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624007482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1525001624007482"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.11.021","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal imaging of therapeutic enzyme expression after gene therapy for Fabry disease using positron emission tomography and the radiotracer [18F]AGAL","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}